|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GUCY1A1 |
Gene summary for GUCY1A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GUCY1A1 | Gene ID | 2982 |
| Gene name | guanylate cyclase 1 soluble subunit alpha 1 | |
| Gene Alias | GC-S-alpha-1 | |
| Cytomap | 4q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q02108 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2982 | GUCY1A1 | TD9 | Human | Lung | IAC | 2.13e-03 | 5.46e-01 | 0.088 |
| 2982 | GUCY1A1 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 1.22e-02 | 5.07e-01 | -0.1408 |
| 2982 | GUCY1A1 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.71e-02 | 4.72e-01 | 0.343 |
| 2982 | GUCY1A1 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 6.23e-01 | 0.3385 |
| 2982 | GUCY1A1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.19e-15 | 6.48e-01 | -0.2116 |
| 2982 | GUCY1A1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.01e-09 | 5.23e-01 | -0.2119 |
| 2982 | GUCY1A1 | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.03e-03 | 3.90e-01 | 0.1829 |
| 2982 | GUCY1A1 | RNA-P3T-P3T-2 | Human | Lung | IAC | 1.31e-02 | 3.74e-01 | 0.1835 |
| 2982 | GUCY1A1 | RNA-P3T-P3T-4 | Human | Lung | IAC | 2.70e-04 | 3.74e-01 | 0.1859 |
| 2982 | GUCY1A1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.53e-24 | 7.14e-01 | -0.0166 |
| 2982 | GUCY1A1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.14e-21 | 6.51e-01 | -0.0132 |
| 2982 | GUCY1A1 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.09e-25 | 7.09e-01 | -0.013 |
| 2982 | GUCY1A1 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 3.41e-16 | 5.69e-01 | -0.0121 |
| 2982 | GUCY1A1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 3.46e-01 | -0.0961 |
| 2982 | GUCY1A1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 2.28e-04 | 4.48e-01 | -0.0876 |
| 2982 | GUCY1A1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.74e-03 | 4.74e-01 | -0.0822 |
| 2982 | GUCY1A1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 4.67e-04 | 4.54e-01 | -0.0809 |
| 2982 | GUCY1A1 | HTA12-23-1 | Human | Pancreas | PDAC | 1.63e-04 | 6.16e-01 | 0.3405 |
| 2982 | GUCY1A1 | HTA12-26-1 | Human | Pancreas | PDAC | 2.20e-04 | 4.35e-01 | 0.3728 |
| 2982 | GUCY1A1 | HTA12-29-1 | Human | Pancreas | PDAC | 5.64e-25 | 6.28e-01 | 0.3722 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091508 | Lung | IAC | purine ribonucleotide metabolic process | 61/2061 | 368/18723 | 7.24e-04 | 9.60e-03 | 61 |
| GO:00091527 | Lung | IAC | purine ribonucleotide biosynthetic process | 33/2061 | 169/18723 | 7.51e-04 | 9.82e-03 | 33 |
| GO:00725218 | Lung | IAC | purine-containing compound metabolic process | 67/2061 | 416/18723 | 9.03e-04 | 1.11e-02 | 67 |
| GO:00030124 | Lung | IAC | muscle system process | 71/2061 | 452/18723 | 1.29e-03 | 1.45e-02 | 71 |
| GO:00092597 | Lung | IAC | ribonucleotide metabolic process | 62/2061 | 385/18723 | 1.38e-03 | 1.53e-02 | 62 |
| GO:00061638 | Lung | IAC | purine nucleotide metabolic process | 63/2061 | 396/18723 | 1.72e-03 | 1.78e-02 | 63 |
| GO:00902577 | Lung | IAC | regulation of muscle system process | 43/2061 | 252/18723 | 2.35e-03 | 2.28e-02 | 43 |
| GO:00092606 | Lung | IAC | ribonucleotide biosynthetic process | 33/2061 | 182/18723 | 2.71e-03 | 2.48e-02 | 33 |
| GO:00196937 | Lung | IAC | ribose phosphate metabolic process | 62/2061 | 396/18723 | 2.72e-03 | 2.49e-02 | 62 |
| GO:00061646 | Lung | IAC | purine nucleotide biosynthetic process | 34/2061 | 191/18723 | 3.21e-03 | 2.78e-02 | 34 |
| GO:00725226 | Lung | IAC | purine-containing compound biosynthetic process | 35/2061 | 200/18723 | 3.75e-03 | 3.14e-02 | 35 |
| GO:00463906 | Lung | IAC | ribose phosphate biosynthetic process | 33/2061 | 190/18723 | 5.39e-03 | 4.04e-02 | 33 |
| GO:000915013 | Lung | AIS | purine ribonucleotide metabolic process | 58/1849 | 368/18723 | 2.33e-04 | 4.68e-03 | 58 |
| GO:000925913 | Lung | AIS | ribonucleotide metabolic process | 59/1849 | 385/18723 | 4.36e-04 | 7.41e-03 | 59 |
| GO:000616313 | Lung | AIS | purine nucleotide metabolic process | 59/1849 | 396/18723 | 8.91e-04 | 1.20e-02 | 59 |
| GO:001969313 | Lung | AIS | ribose phosphate metabolic process | 59/1849 | 396/18723 | 8.91e-04 | 1.20e-02 | 59 |
| GO:007252113 | Lung | AIS | purine-containing compound metabolic process | 61/1849 | 416/18723 | 1.10e-03 | 1.42e-02 | 61 |
| GO:000915213 | Lung | AIS | purine ribonucleotide biosynthetic process | 29/1849 | 169/18723 | 2.24e-03 | 2.38e-02 | 29 |
| GO:000301211 | Lung | AIS | muscle system process | 63/1849 | 452/18723 | 3.18e-03 | 3.05e-02 | 63 |
| GO:0019932 | Lung | AIS | second-messenger-mediated signaling | 46/1849 | 312/18723 | 3.79e-03 | 3.52e-02 | 46 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04921 | Lung | IAC | Oxytocin signaling pathway | 33/1053 | 154/8465 | 1.09e-03 | 7.82e-03 | 5.19e-03 | 33 |
| hsa046114 | Lung | IAC | Platelet activation | 27/1053 | 124/8465 | 2.34e-03 | 1.23e-02 | 8.14e-03 | 27 |
| hsa049211 | Lung | IAC | Oxytocin signaling pathway | 33/1053 | 154/8465 | 1.09e-03 | 7.82e-03 | 5.19e-03 | 33 |
| hsa0461112 | Lung | IAC | Platelet activation | 27/1053 | 124/8465 | 2.34e-03 | 1.23e-02 | 8.14e-03 | 27 |
| hsa049212 | Lung | AIS | Oxytocin signaling pathway | 34/961 | 154/8465 | 9.12e-05 | 1.18e-03 | 7.57e-04 | 34 |
| hsa0461121 | Lung | AIS | Platelet activation | 26/961 | 124/8465 | 1.33e-03 | 9.38e-03 | 6.00e-03 | 26 |
| hsa049213 | Lung | AIS | Oxytocin signaling pathway | 34/961 | 154/8465 | 9.12e-05 | 1.18e-03 | 7.57e-04 | 34 |
| hsa046113 | Lung | AIS | Platelet activation | 26/961 | 124/8465 | 1.33e-03 | 9.38e-03 | 6.00e-03 | 26 |
| hsa049214 | Lung | AAH | Oxytocin signaling pathway | 17/348 | 154/8465 | 1.87e-04 | 8.70e-03 | 6.99e-03 | 17 |
| hsa049215 | Lung | AAH | Oxytocin signaling pathway | 17/348 | 154/8465 | 1.87e-04 | 8.70e-03 | 6.99e-03 | 17 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2982 | GUCY1A1 | ENZYME, DRUGGABLE GENOME | activator | CHEMBL730 | NITROGLYCERIN | |
| 2982 | GUCY1A1 | ENZYME, DRUGGABLE GENOME | activator | CHEMBL136478 | SODIUM NITROPRUSSIDE | |
| 2982 | GUCY1A1 | ENZYME, DRUGGABLE GENOME | activator | CHEMBL6622 | ISOSORBIDE DINITRATE | |
| 2982 | GUCY1A1 | ENZYME, DRUGGABLE GENOME | activator | CHEMBL1311 | ISOSORBIDE MONONITRATE | |
| 2982 | GUCY1A1 | ENZYME, DRUGGABLE GENOME | activator | CHEMBL1200689 | NITRIC OXIDE | |
| 2982 | GUCY1A1 | ENZYME, DRUGGABLE GENOME | RIOCIGUAT | RIOCIGUAT | ||
| 2982 | GUCY1A1 | ENZYME, DRUGGABLE GENOME | positive modulator | CHEMBL2107834 | RIOCIGUAT |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |